Approval · Notice of Compliance 2071 · 1999
AGGRASTAT: Notice of Compliance 2071
Issued August 19, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2071
- Date
- August 19, 1999
- Company
- Merck Frosst Canada Inc.Kirkland, QC, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Platelet aggregation inhibitor
Products in this notice
Medicinal ingredients
- TIROFIBAN HCL 0.25 MG per ML
- TIROFIBAN HCL 5 MG per 100ML